BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

BELLUS Health, a clinical-stage biopharmaceutical company, announced that President and CEO Roberto Bellini will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:30 a.m. ET. This event will focus on the development of novel therapeutics for refractory chronic cough (RCC) and other disorders related to hypersensitization. The live webcast can be accessed on the company's website, with an archived version available post-event.

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference.

Presentation Details:

Event: Jefferies Virtual Healthcare Conference

Date/Time: Tuesday, June 1, 2021 at 10:30 a.m. ET

A live webcast of fireside chat may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of RCC and chronic pruritus associated with AD.

RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and current treatment options are limited.

Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD, there continues to be a lack of options targeting the burden of pruritus in patients with AD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005341/en/

FAQ

What is the date and time of BELLUS Health's presentation at the Jefferies Virtual Healthcare Conference?

BELLUS Health's presentation is scheduled for June 1, 2021, at 10:30 a.m. ET.

How can I access the live webcast of the BELLUS Health fireside chat?

You can access the live webcast on BELLUS Health's website under the Events & Presentations section.

What is the primary focus of BELLUS Health's research?

BELLUS Health focuses on developing therapeutics for refractory chronic cough (RCC) and other hypersensitization-related disorders.

What are the symptoms associated with refractory chronic cough?

Refractory chronic cough is defined as a cough lasting more than 8 weeks despite treatment for underlying conditions.

What is the estimated prevalence of refractory chronic cough in the United States?

Approximately 9 million patients in the United States suffer from refractory chronic cough.

What condition is associated with chronic pruritus that BELLUS Health is addressing?

BELLUS Health is also developing treatments for chronic pruritus associated with atopic dermatitis (AD).

What percentage of adults in the U.S. suffer from atopic dermatitis?

It is estimated that up to 10% of adults in the United States suffer from atopic dermatitis.